TEVA, US8816242098

Teva stock: Guidance lift meets Samsung Bioepis valuation test

Published on 11/10/2026 at 10:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Teva stock faces a valuation test after higher 2026 guidance and a Samsung Bioepis biosimilars agreement. Execution risks remain.

Growth Story Meets Execution Risk

Teva's branded-drug strategy and biosimilars expansion support the company's updated growth narrative.
Lower net income and pipeline execution risks remain important counterweights for investors.

TEVA, US8816242098, Illustration mit AI erstellt.

Teva stock faces a fresh valuation test after Simply Wall St reviewed the drugmaker's higher 2026 revenue outlook and its Samsung Bioepis biosimilars agreement on Tuesday, November 10. The Simply Wall St analysis said third-quarter net income was lower year over year, even as management raised its 2026 revenue guidance.

Branded Drugs Support The Pivot

The analysis highlights Teva's shift toward higher-value branded central nervous system medicines, including AUSTEDO, AJOVY and UZEDY. That mix is increasing the share of sales linked to products with higher gross margins and supports management's longer-term objective of a 30% non-GAAP operating margin and a larger EBITDA contribution.

The Samsung Bioepis agreement broadens Teva's immunology biosimilars footprint. For investors, the deal adds to the growth case, but its contribution will depend on commercial execution, market uptake and the company's ability to offset pressure in generic medicines.

Valuation Depends On Execution

Simply Wall St's narrative assessment places fair value at 48.94 US dollars, above the latest cited close of 42.97 US dollars. The analysis therefore presents potential upside, but it also stresses that the valuation case depends on delivery across the branded portfolio and the biosimilars business.

Pipeline risk remains a central counterweight. The recent emrusolmin Phase 2 stop and the possibility of weaker-than-expected biosimilar uptake could reduce the support for Teva's growth narrative and increase the importance of execution in established products.